AAS
TSHA icon

Ameritas Advisory Services’s Taysha Gene Therapies TSHA Stock Holding History

Ameritas Advisory Services’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$4 – 2120
2026
Q1 		$4 Buy
+1
New +$5 ﹤0.01% 1075

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameritas Advisory Services's TSHA Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 1 share — an estimated $4 sold.

Ameritas Advisory Services first reported a position in TSHA in Q1 2026 and held it in 1 quarter. The position peaked at $4 in Q1 2026. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 1 Taysha Gene Therapies share in Q2 2026, an estimated $4.
  • Ameritas Advisory Services first reported a position in Taysha Gene Therapies in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Taysha Gene Therapies position peaked at $4 in Q1 2026.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.